Beyond The Numbers: 7 Analysts Discuss Humana Stock
Portfolio Pulse from Benzinga Insights
Seven analysts have recently updated their ratings on Humana (NYSE:HUM), with a mix of bullish and indifferent stances. The average 12-month price target is $588.29, slightly up from the previous $587.33. Analysts from firms like Oppenheimer, Argus Research, and JP Morgan have maintained or adjusted their ratings and price targets. Humana has shown strong financial performance with a revenue growth of 15.9%, a net margin of 3.15%, and an ROE of 4.93%, but it has a high debt-to-equity ratio of 0.71.
January 17, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts have a mixed outlook on Humana, with recent ratings ranging from bullish to indifferent. The average price target has slightly increased, indicating a positive sentiment. Humana's strong financial performance could support a positive short-term impact on the stock.
The slight increase in the average price target and the strong financial performance of Humana, including revenue growth and net margin, suggest a positive outlook that could lead to a short-term increase in stock price. However, the high debt-to-equity ratio could be a concern for some investors, potentially moderating the impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100